此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

对哥斯达黎加接种 16 型和 18 型人乳头瘤病毒疫苗的年轻女性以及未接种疫苗的对照进行扩展随访

2026年11月17日 更新者:National Cancer Institute (NCI)

This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls. Collecting information from young women in Costa Rica who have received vaccine for human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for the follow-up period, may help doctors learn more about the risks and benefits of prophylactic human papillomavirus vaccine.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To evaluate the 10-year global impact of human papillomavirus (HPV)-16/18 vaccination of young adult women.

II. To evaluate determinants of the immune response to HPV and the vaccine, and markers of long-term protection.

III. To evaluate the natural history of HPV and cervical disease in vaccinated and unvaccinated populations.

OUTLINE:

Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.

研究类型

观察性的

注册 (估计的)

8670

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Guanacaste Province
      • Liberia、Guanacaste Province、哥斯达黎加、50101
        • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

是的

有资格学习的性别

女性

取样方法

非概率样本

研究人群

Young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls.

描述

Inclusion Criteria:

  • Women who participated in the Costa Rica Vaccine Trial (CVT) and lived in the Guanacaste province and a few areas of Puntarenas closest to Guanacaste will be eligible for the long-term follow up LTFU study
  • Women who received the HPV-16/18 vaccine at the start of CVT will be invited for up to 6 years of additional follow-up, and women who were originally in the control arm of CVT and were offered the HPV-16/18 vaccine at crossover will be invited for an additional 2 years of follow-up
  • A subset of the control arm women who are in the crossover immunogenicity subcohort will be followed the full 6 years
  • Some women who received HPV vaccination and were not invited into the LTFU protocol (stopped attending their screening visits during CVT, discontinued their study participation during CVT or lived outside the study area) will be invited to participate in the LTFU protocol, particularly those who received an incomplete vaccination schedule
  • UNVACCINATED CONTROL GROUP:
  • Born in or between July 1978 and November 1987
  • Residents of Guanacaste Province and a few areas of Puntarenas closest to Guanacaste at some point during 2005
  • Able to speak/understand Spanish
  • Apparently mentally competent
  • Written informed consent obtained prior to enrollment

Exclusion Criteria:

  • History of cervical cancer
  • History of hysterectomy
  • Any important medical condition or other criteria that the investigator considers that precludes enrollment
  • Vaccination with Gardasil or Cervarix will be an exclusionary criterion, but few women are expected to have received these vaccines at the time of enrollment; use of these vaccines after enrollment is not a criterion for study interruption but we plan to collect information on vaccination history so that the few women who report having been vaccinated with one of the HPV vaccines after enrollment can be evaluated separately at analysis

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Observational (long term follow-up)

Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.

Correlative studies

Ancillary studies

Correlative studies

其他名称:
  • 细胞学取样

Undergo extended follow-up

其他名称:
  • 长期随访(临床研究)
  • LTFU
  • 长期随访(研究)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cumulative rate of cervical intraepithelial neoplasia 3 (CIN3)
大体时间:At 10 years

Both absolute rate differences and percent reduction in rates will be evaluated.

At 10 years
Level of immune response markers as prediction of long-term success of HPV vaccine
大体时间:Up to 10 years

For efficiency, a nested case-control approach is envisioned to evaluate this question. We propose to compare women who become infected against a subset of those who do not (non-failures) with respect to immune response markers of interest.

Up to 10 years
Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination
大体时间:Up to 10 years

The 10-year cumulative rate of incident CIN2+ associated with HPV types other than HPV-16/18 and closely related HPV types in the alpha-7/9 species for which evidence of vaccine cross-protection is demonstrated will be compared between vaccinated and unvaccinated women.

Up to 10 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Aimee Kreimer、National Cancer Institute (NCI)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2009年3月30日

初级完成 (估计的)

2026年12月23日

研究完成 (估计的)

2026年12月23日

研究注册日期

首次提交

2009年3月20日

首先提交符合 QC 标准的

2009年3月20日

首次发布 (估计的)

2009年3月23日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅